Comparison of three commercial tests for buprenorphine screening in urine

Ann Clin Biochem 2007;44:563-565
© 2007 Association for Clinical Biochemistry


This Article

Full Text (PDF)

Alert me when this article is cited

Alert me if a correction is posted

Email this article to a friend

Similar articles in this journal

Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Citing Articles

Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar

Articles by Leino, A.

Articles by Loo, B.-M.
Search for Related Content

PubMed Citation
Social Bookmarking

What’s this?

Short Reports

Aila Leino and
Britt-Marie Loo

TYKSLAB Laboratory, Hospital District of Southwest Finland; Department of Clinical Chemistry, Turku University Central Hospital, Kiinamyllynkatu, Turku, Finland; The Joint Clinical Biochemistry Laboratory of University of Turku, Turku University Central Hospital and Wallac Ltd, Kiinamyllynkatu 4-8, Turku, Finland;
TYKSLAB Laboratory, Hospital District of Southwest Finland

Background: Rapid and sensitive tests for detecting buprenorphineand its metabolites for drug-screening situations have beenlong awaited. From the tests available, we have evaluated twoon-site drugs-of-abuse testing devices using competitive bindingimmunoassays and one homogeneous enzyme immunoassay measuredon an automated analyser.

Methods: A total of 49 urine specimens were tested using three different kits. Two were point-of-care devices, a cassette test, QuikPac II OneStep Buprenorphine Test, and a strip test, QuikStrip OneStep Buprenorphine Test. The other was the CEDIA® BuprenorphineAssay performed on a Roche Modular P analyser. The confirmationanalyses were performed using liquid chromatography-mass spectrometry.

Results: The sensitivities of the three methods ranged from88% to 100% and specificities from 91% to 100%. All three kits,especially the cassette and strip devices differed markedlyfrom each other with respect to interpretation of the test resultand to clarity of the test performance. Increasing the readtime of the QuikStrip device from 5 to 30 min resulted in anincrease in false-negative test results.

Conclusions: Our results indicate that special care should betaken when selecting immunology-based point-of-care methodsfor measurement of buprenorphine.

CiteULike    Complore    Connotea    Digg    Reddit    Technorati    What’s this?

This article has been cited by other articles:

S. Twigger, E. Fox, and K. Allen
Measurement of buprenorphine in urine: immunoassay versus LC-MS/MS
Ann Clin Biochem,

May 1, 2008;
339 – 339.

[Full Text]